Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week
or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer